TTR amyloidosis
Centogene, Alnylam Pharmaceuticals Partner on Biomarker Study of Transthyretin Amyloidosis
The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene.
Alnylam, 23andMe Partner on Free Family Testing Program for Hereditary ATTR Amyloidosis
23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.
Akcea, Ambry Genetics to Launch Genetic Testing Program for ATTR Amyloidosis
The effort will provide individuals with genetic testing to determine if they have the disorder, and when necessary, with genetic testing counselling.
The probes let researchers analyze oligomeric aggregates linked to forms of amyloidosis and could aid early diagnosis or monitoring response to therapy.
Invitae, Alnylam to Provide Free Genetic Testing for Rare Amyloidosis Condition
Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it.